Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates.
In this cohort study, researchers identified 6146 patients from 17 registries of the SEER Program who had been diagnosed with a first primary cutaneous Merkel cell carcinoma between 2000 and 2018.
A new analysis found that relapse-free survival is a poor surrogate endpoint for overall survival in adjuvant immunotherapy trials in a variety of cancer types.